Compare DLR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLR | BSX |
|---|---|---|
| Founded | 2004 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7B | 65.8B |
| IPO Year | 2004 | 2010 |
| Metric | DLR | BSX |
|---|---|---|
| Price | $200.27 | $51.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 22 |
| Target Price | ★ $207.95 | $93.18 |
| AVG Volume (30 Days) | 2.7M | ★ 18.3M |
| Earning Date | 04-23-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 122.36 | 55.20 |
| EPS | 0.46 | ★ 1.51 |
| Revenue | $6,112,692,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | $11.07 | $11.85 |
| Revenue Next Year | $10.54 | $10.16 |
| P/E Ratio | $429.57 | ★ $34.25 |
| Revenue Growth | 10.04 | ★ 12.49 |
| 52 Week Low | $146.23 | $42.20 |
| 52 Week High | $208.14 | $109.50 |
| Indicator | DLR | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 72.86 |
| Support Level | $172.54 | $42.32 |
| Resistance Level | $207.81 | $58.35 |
| Average True Range (ATR) | 4.80 | 1.66 |
| MACD | 0.83 | 0.62 |
| Stochastic Oscillator | 92.96 | 91.05 |
Digital Realty is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and large businesses. Digital Realty operates 300 properties in 57 metropolitan areas across 31 countries, serving 5,000 customers. Renting physical space accounts for about 90% of Digital Realty's revenue. The firm enables hyperscalers and other clients to store servers, data, and networking equipment. The other 10% of revenue is generated primarily through interconnection services (8%) and other fee income (2%).
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.